or Try an Advanced Search...

    Technical Analysis for PHAT - Phathom Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    C 11.74 4.08% 0.46
    PHAT closed up 4.08 percent on Friday, July 26, 2024, on 1.33 times normal volume.
    Earnings due: Aug 8
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Flat
    Historical PHAT trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Outside Day Range Expansion 0.00%
    MACD Bearish Signal Line Cross Bearish 4.08%
    20 DMA Support Bullish 4.08%
    NR7 Range Contraction 4.08%
    NR7-2 Range Contraction 4.08%
    Gapped Up Strength 4.08%
    NR7 Range Contraction 2.44%
    Spinning Top Other -3.22%
    Older End-of-Day Signals for PHAT ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 10 hours ago
    Rose Above 10 DMA about 10 hours ago
    Outside Day about 10 hours ago
    10 DMA Resistance about 10 hours ago
    Up 3% about 12 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PHAT Chart by TradingView
    Basic chart:

    Profile

    Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Life Sciences Acid Natural Sciences Medication Gastrointestinal Disorders Potassium Gastrointestinal Disease Tadataka Yamada

    Is PHAT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 18 Phathom Pharma announces Voquezna label expansion
    Jul 18 Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
    Jun 26 Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
    Jun 9 Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
    Jun 7 Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
    May 28 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    May 15 Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
    May 13 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
    May 11 Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
    May 10 The 3 Best Healthcare Stocks to Buy in May 2024
    See more PHAT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.0
    52 Week Low 6.065
    Average Volume 647,723
    200-Day Moving Average 9.31
    50-Day Moving Average 10.85
    20-Day Moving Average 11.19
    10-Day Moving Average 11.76
    Average True Range 0.85
    RSI (14) 54.95
    ADX 18.38
    +DI 17.79
    -DI 15.42
    Chandelier Exit (Long, 3 ATRs) 10.45
    Chandelier Exit (Short, 3 ATRs) 12.35
    Upper Bollinger Bands 12.69
    Lower Bollinger Band 9.70
    Percent B (%b) 0.68
    BandWidth 26.75
    MACD Line 0.27
    MACD Signal Line 0.27
    MACD Histogram 0.002
    Fundamentals Value
    Market Cap 672.14 Million
    Num Shares 57.3 Million
    EPS -3.81
    Price-to-Earnings (P/E) Ratio -3.08
    Price-to-Sales 0.00
    Price-to-Book 25.37
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.84
    Resistance 3 (R3) 12.74 12.29 12.65
    Resistance 2 (R2) 12.29 12.01 12.33 12.59
    Resistance 1 (R1) 12.01 11.84 12.15 12.11 12.53
    Pivot Point 11.56 11.56 11.63 11.60 11.56
    Support 1 (S1) 11.28 11.28 11.42 11.38 10.95
    Support 2 (S2) 10.83 11.11 10.87 10.89
    Support 3 (S3) 10.55 10.83 10.83
    Support 4 (S4) 10.65